Work

Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome)

Year: 2014

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdu231

Authors: R. Dummer, M. Duvic, J. Scarisbrick, E.A. Olsen, S. Rozati, N. Eggmann, S.M. Goldinger, K. Hutchinson, L. Geskin, T.M. Illidge, E. Giuliano, J. Elder, Y.H. Kim

Institutions: University Hospital Zurich, The University of Texas MD Anderson Cancer Center, Duke Medical Center, University of Pittsburgh, University of Manchester, BioCryst Pharmaceuticals (United States), Stanford University

Language: English

Topic: Cutaneous lymphoproliferative disorders research

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: BioCryst

OpenAlex ID: W2162556084

FWCI: 6.58

Cites: 24

Cited by: 43

Related to: 10